指南与共识重症综合管理与镇静镇痛

麻醉中肌肉松弛剂与拮抗指南

Guidelines on muscle relaxants and reversal in anaesthesia.
指南 / 共识 · Anaesth Crit Care Pain Med · 2020-01-08
一句话结论法国麻醉与重症监护学会(SFAR)推荐在整个麻醉期间使用神经肌肉阻滞监测装置。

法国麻醉与重症监护学会(SFAR)召集16位专家,按GRADE系统更新1999年指南,聚焦8个PICO问题:面罩通气、气管插管、声门上装置、气道管理中的神经肌肉阻滞监测、介入操作、术中监测、残余阻滞防治及特殊人群用药。共形成31条推荐,其中11条为高证据级别(GRADE 1±),20条为低证据级别(GRADE 2±);5个问题无法用GRADE系统给出推荐,其中2个问题给出专家意见。所有推荐经两轮讨论与修订后达成强烈共识。SFAR特别推荐在整个麻醉期间使用神经肌肉阻滞监测装置。

要点

  • SFAR推荐在整个麻醉期间使用神经肌肉阻滞监测装置(结论部分明确推荐)。
  • 31条推荐中11条为高证据级别(GRADE 1±),20条为低证据级别(GRADE 2±)。
  • 5个问题无法用GRADE系统给出推荐,其中2个问题给出专家意见。
  • 所有推荐经两轮讨论与修订后达成强烈共识。
  • 指南强调基于低质量证据做出强推荐可能存在的弊端。

适用人群与场景

  • 接受麻醉并使用肌肉松弛剂和/或拮抗剂的患者,包括特殊人群:电休克治疗、肥胖患者、儿童、神经肌肉疾病、肾/肝功能衰竭、老年患者。

处置流程与药物剂量

  • SFAR推荐在整个麻醉期间使用神经肌肉阻滞监测装置。

研究设计与关键结果

  • SFAR指南专家组共形成31条关于麻醉中肌肉松弛剂与拮抗剂的推荐。
  • 31条推荐中11条为高证据级别(GRADE 1±),20条为低证据级别(GRADE 2±)。
  • 5个问题无法使用GRADE系统给出推荐,其中2个问题给出了专家意见。
  • 经两轮讨论与修订后,所有推荐均达成强烈共识。

证据类型、等级与局限

  • 证据类型:指南(共识委员会,16位专家,采用GRADE系统评估证据质量与推荐强度)。
  • 推荐强度:11条高证据级别(GRADE 1±),20条低证据级别(GRADE 2±)。
  • 5个问题无法用GRADE系统给出推荐,其中2个问题给出专家意见。
  • 指南制定过程独立于任何工业资助,并实施利益冲突声明与监控政策。
  • 指南强调基于低质量证据做出强推荐可能存在的弊端。
  • 局限:原文未报告局限性

对床旁实践的改变

  • SFAR推荐在整个麻醉期间使用神经肌肉阻滞监测装置,这支持在麻醉全程(不仅是诱导或苏醒期)常规开展神经肌肉阻滞监测。
  • 指南覆盖面罩通气、气管插管、声门上装置置入、介入操作及特殊人群用药等8个临床问题,共31条推荐可供床旁参照。

指南或共识出处

  • 指南名称:Guidelines on muscle relaxants and reversal in anaesthesia;发布机构:法国麻醉与重症监护学会(SFAR);发表期刊:Anaesth Crit Care Pain Med。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To provide an update to the 1999 French guidelines on "Muscle relaxants and reversal in anaesthesia", a consensus committee of sixteen experts was convened. A formal policy of declaration and monitoring of conflicts of interest (COI) was developed at the outset of the process and enforced throughout. The entire guidelines process was conducted independently of any industrial funding (i.e. pharmaceutical, medical devices). The authors were required to follow the rules of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE®) system to assess the quality of the evidence on which the recommendations were based. The potential drawbacks of making strong recommendations based on low-quality evidence were stressed. Few of the recommendations remained ungraded.

METHODS: The panel focused on eight questions: (1) In the absence of difficult mask ventilation criteria, is it necessary to check the possibility of ventilation via a facemask before muscle relaxant injection? Is it necessary to use muscle relaxants to facilitate facemask ventilation? (2) Is the use of muscle relaxants necessary to facilitate tracheal intubation? (3) Is the use of muscle relaxants necessary to facilitate the insertion of a supraglottic device and management of related complications? (4) Is it necessary to monitor neuromuscular blockade for airway management? (5) Is the use of muscle relaxants necessary to facilitate interventional procedures, and if so, which procedures? (6) Is intraoperative monitoring of neuromuscular blockade necessary? (7) What are the strategies for preventing and treating residual neuromuscular blockade? (8) What are the indications and precautions for use of both muscle relaxants and reversal agents in special populations (e.g. electroconvulsive therapy, obese patients, children, neuromuscular diseases, renal/hepatic failure, elderly patients)? All questions were formulated using the Population, Intervention, Comparison and Outcome (PICO) model for clinical questions and evidence profiles were generated. The results of the literature analysis and the recommendations were then assessed using the GRADE® system.

RESULTS: The summaries prepared by the SFAR Guideline panel resulted in thirty-one recommendations on muscle relaxants and reversal agents in anaesthesia. Of these recommendations, eleven have a high level of evidence (GRADE 1±) while twenty have a low level of evidence (GRADE 2±). No recommendations could be provided using the GRADE® system for five of the questions, and for two of these questions expert opinions were given. After two rounds of discussion and an amendment, a strong agreement was reached for all the recommendations.

CONCLUSION: Substantial agreement exists among experts regarding many strong recommendations for the improvement of practice concerning the use of muscle relaxants and reversal agents during anaesthesia. In particular, the French Society of Anaesthesia and Intensive Care (SFAR) recommends the use of a device to monitor neuromuscular blockade throughout anaesthesia.

来源:Anaesth Crit Care Pain Med,查看原文。版权归原作者所有。

参考来源

  1. Plaud B, Baillard C, Bourgain JL, et al. Guidelines on muscle relaxants and reversal in anaesthesia. Anaesth Crit Care Pain Med. 2020. PMID: 31926308. doi:10.1016/j.accpm.2020.01.005

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。